Vita Life SciencesASX:VLS 94 Median PS Value is A$2.30 as of Jun. 25, 2026, which is 100% below its 10-year median of 0.92. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 544 Drug Manufacturers companies, Vita Life Sciences ranks worse than 67.1% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Vita Life Sciences's Median PS Value or its related term are showing as below:
ASX:VLS'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63 Med: 0.92 Max: 1.21
Current: 1.09
During the past 13 years, the highest Price to Median PS Value of Vita Life Sciences was 1.21. The lowest was 0.63. And the median was 0.92.
ASX:VLS's Price-to-Median-PS-Value is ranked worse than 67.1% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.84
vs ASX:VLS: 1.09
Vita Life Sciences (ASX:VLS) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Vita Life Sciences's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.50
/
2.30
=
1.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences Median PS Value Related Terms
Vita Life Sciences Median PS Value Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.4024.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vita Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.64.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a Median PS Value of A$2.30 as of Jun. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Vita Life Sciences and its competitors. This is 150% above median its historical median of 0.92. Over the past decade, Vita Life Sciences' Median PS Value has ranged from 0.63 to 1.21. According to the industry distribution chart, Vita Life Sciences ranks #365 out of 544 companies in the Drug Manufacturers industry, placing it in the top 67.1%.
Is Vita Life Sciences' Median PS Value too high?
Vita Life Sciences' current Median PS Value of A$2.30 is 150% above median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 1.21. Based on the distribution chart, Vita Life Sciences ranks #365 out of 544 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Median PS Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #365 out of 544 companies for Median PS Value. This places Vita Life Sciences in the lower half of its industry. The industry median Median PS Value is 0.84. Historically, Vita Life Sciences' own Median PS Value has ranged from 0.63 to 1.21 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.84, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Median PS Value is A$2.30, which is 150% above median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current Median PS Value is A$2.30, which is 150% above median its 10-year median of 0.92. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Median PS Value is A$2.30 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Median PS Value: A$2.30 (150% above median its 10-year median of 0.92)
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score
Get the complete analysis for ASX:VLS
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
